Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial

AJ. Coles, DL. Arnold, AD. Bass, AL. Boster, DAS. Compston, Ó. Fernández, EK. Havrdová, K. Nakamura, A. Traboulsee, T. Ziemssen, A. Jacobs, DH. Margolin, X. Huang, N. Daizadeh, MC. Chirieac, KW. Selmaj

. 2021 ; 14 (-) : 1756286420982134. [pub] 20210423

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21017911

Background: In the 2-year CARE-MS I and II trials, alemtuzumab 12 mg administered on 5 consecutive days at core study baseline and on 3 consecutive days 12 months later significantly improved outcomes versus subcutaneous interferon beta-1a (SC IFNB-1a) in relapsing-remitting multiple sclerosis patients. Here, we present the final 6-year CARE-MS extension trial results (CAMMS03409), and compare outcomes over 6 years in patients randomized to both treatment groups at core study baseline. Methods: Over a 4-year extension, alemtuzumab patients (alemtuzumab-only) received as-needed additional alemtuzumab (⩾12 months apart) for disease activity after course 2. SC IFNB-1a patients who entered the extension discontinued SC IFNB-1a and received 2 alemtuzumab 12 mg courses (IFN-alemtuzumab), followed by additional, as-needed, alemtuzumab. Results: Through year 6, 63% of CARE-MS I and 50% of CARE-MS II alemtuzumab-only patients received neither additional alemtuzumab nor other disease-modifying therapy, with lasting suppression of disease activity, improved disability, and slowing of brain volume loss (BVL). In CARE-MS I patients (treatment-naive; less disability; shorter disease duration), disease activity and BVL were significantly reduced in IFN-alemtuzumab patients, similar to alemtuzumab-only patients at year 6. Among CARE-MS II patients (inadequate response to prior treatment; more disability; longer disease duration), alemtuzumab significantly improved clinical and magnetic resonance imaging outcomes, including BVL, in IFN-alemtuzumab patients; however, disability outcomes were less favorable versus alemtuzumab-only patients. Safety profiles, including infections and autoimmunities, following alemtuzumab were similar between treatment groups. Conclusion: This study demonstrates the high efficacy of alemtuzumab over 6 years, with a similar safety profile between treatment groups. ClinicalTrialsgov identifiers: NCT00530348; NCT00548405; NCT00930553.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21017911
003      
CZ-PrNML
005      
20210729104202.0
007      
ta
008      
210726s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1177/1756286420982134 $2 doi
035    __
$a (PubMed)34035833
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Coles, Alasdair J $u Department of Clinical Neurosciences, University of Cambridge, Box 165, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK
245    10
$a Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial / $c AJ. Coles, DL. Arnold, AD. Bass, AL. Boster, DAS. Compston, Ó. Fernández, EK. Havrdová, K. Nakamura, A. Traboulsee, T. Ziemssen, A. Jacobs, DH. Margolin, X. Huang, N. Daizadeh, MC. Chirieac, KW. Selmaj
520    9_
$a Background: In the 2-year CARE-MS I and II trials, alemtuzumab 12 mg administered on 5 consecutive days at core study baseline and on 3 consecutive days 12 months later significantly improved outcomes versus subcutaneous interferon beta-1a (SC IFNB-1a) in relapsing-remitting multiple sclerosis patients. Here, we present the final 6-year CARE-MS extension trial results (CAMMS03409), and compare outcomes over 6 years in patients randomized to both treatment groups at core study baseline. Methods: Over a 4-year extension, alemtuzumab patients (alemtuzumab-only) received as-needed additional alemtuzumab (⩾12 months apart) for disease activity after course 2. SC IFNB-1a patients who entered the extension discontinued SC IFNB-1a and received 2 alemtuzumab 12 mg courses (IFN-alemtuzumab), followed by additional, as-needed, alemtuzumab. Results: Through year 6, 63% of CARE-MS I and 50% of CARE-MS II alemtuzumab-only patients received neither additional alemtuzumab nor other disease-modifying therapy, with lasting suppression of disease activity, improved disability, and slowing of brain volume loss (BVL). In CARE-MS I patients (treatment-naive; less disability; shorter disease duration), disease activity and BVL were significantly reduced in IFN-alemtuzumab patients, similar to alemtuzumab-only patients at year 6. Among CARE-MS II patients (inadequate response to prior treatment; more disability; longer disease duration), alemtuzumab significantly improved clinical and magnetic resonance imaging outcomes, including BVL, in IFN-alemtuzumab patients; however, disability outcomes were less favorable versus alemtuzumab-only patients. Safety profiles, including infections and autoimmunities, following alemtuzumab were similar between treatment groups. Conclusion: This study demonstrates the high efficacy of alemtuzumab over 6 years, with a similar safety profile between treatment groups. ClinicalTrialsgov identifiers: NCT00530348; NCT00548405; NCT00930553.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Arnold, Douglas L $u NeuroRx Research, Montréal, Québec, Canada
700    1_
$a Bass, Ann D $u Neurology Center of San Antonio, San Antonio, TX, USA
700    1_
$a Boster, Aaron L $u The Boster MS Center, Columbus, OH, USA
700    1_
$a Compston, D Alastair S $u Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK
700    1_
$a Fernández, Óscar $u Instituto de Investigación Biomédica de Málaga (IBIMA), Málaga, Spain
700    1_
$a Havrdová, Eva Kubala $u Department of Neurology and Center for Clinical Neuroscience, First Medical Faculty, Charles University, Prague, Czech Republic
700    1_
$a Nakamura, Kunio $u Department of Biomedical Engineering, Cleveland Clinic, Cleveland, OH, USA
700    1_
$a Traboulsee, Anthony $u The University of British Columbia, Vancouver, British Columbia, Canada
700    1_
$a Ziemssen, Tjalf $u Center of Clinical Neuroscience, Carl Gustav Carus University Hospital, Dresden, Germany
700    1_
$a Jacobs, Alan $u Immunovant, Inc., New York, NY, USA
700    1_
$a Margolin, David H $u Cerevance, Inc., Boston, MA, USA
700    1_
$a Huang, Xiaobi $u Sanofi, Cambridge, MA, USA
700    1_
$a Daizadeh, Nadia $u Sanofi, Cambridge, MA, USA
700    1_
$a Chirieac, Madalina C $u Vertex Pharmaceuticals, Inc., Boston, MA, USA
700    1_
$a Selmaj, Krzysztof W $u Department of Neurology, University of Warmia and Mazury, Olsztyn, Poland
773    0_
$w MED00177176 $t Therapeutic advances in neurological disorders $x 1756-2856 $g Roč. 14, č. - (2021), s. 1756286420982134
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34035833 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20210726 $b ABA008
991    __
$a 20210729104200 $b ABA008
999    __
$a ind $b bmc $g 1676461 $s 1138353
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 14 $c - $d 1756286420982134 $e 20210423 $i 1756-2856 $m Therapeutic advances in neurological disorders $n Ther Adv Neurol Disord $x MED00177176
LZP    __
$a Pubmed-20210726

Najít záznam

Citační ukazatele

Možnosti archivace